메뉴 건너뛰기




Volumn 8, Issue 3, 2013, Pages 173-181

The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: A systematic review and meta-analysis of published trials

Author keywords

Cetuximab; Colorectal cancer; Panitumumab; Response; Skin rash; Survival

Indexed keywords

CAPECITABINE; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IRINOTECAN; MITOMYCIN; OXALIPLATIN; PANITUMUMAB;

EID: 84884288905     PISSN: 17762596     EISSN: 1776260X     Source Type: Journal    
DOI: 10.1007/s11523-013-0257-x     Document Type: Review
Times cited : (105)

References (32)
  • 1
    • 34147103678 scopus 로고    scopus 로고
    • Open-label phase iii trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy- refractory metastatic colorectal cancer
    • 17470858 10.1200/JCO.2006.08.1620
    • Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon J-L, Van Laethem J-L et al (2007) Open-label phase iii trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25(13):1658-1664
    • (2007) J Clin Oncol , vol.25 , Issue.13 , pp. 1658-1664
    • Van Cutsem, E.1    Peeters, M.2    Siena, S.3    Humblet, Y.4    Hendlisz, A.5    Neyns, B.6    Canon, J.-L.7    Van Laethem, J.-L.8
  • 2
    • 42649145667 scopus 로고    scopus 로고
    • Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
    • 18316791 10.1200/JCO.2007.14.7116 1:CAS:528:DC%2BD1cXltlWhsrw%3D
    • Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26(10):1626-1634
    • (2008) J Clin Oncol , vol.26 , Issue.10 , pp. 1626-1634
    • Amado, R.G.1    Wolf, M.2    Peeters, M.3    Van Cutsem, E.4    Siena, S.5    Freeman, D.J.6    Juan, T.7    Sikorski, R.8
  • 4
    • 84984568870 scopus 로고    scopus 로고
    • Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities
    • MASCC Skin Toxicity Study Group 21630130 10.1007/s00520-011-1197-6 Epub 2011 Jun 1
    • Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB, Eaby-Sandy B, Murphy BA, MASCC Skin Toxicity Study Group (2011) Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 19(8):1079-1095, Epub 2011 Jun 1
    • (2011) Support Care Cancer , vol.19 , Issue.8 , pp. 1079-1095
    • Lacouture, M.E.1    Anadkat, M.J.2    Bensadoun, R.J.3    Bryce, J.4    Chan, A.5    Epstein, J.B.6    Eaby-Sandy, B.7    Murphy, B.A.8
  • 5
    • 79952601240 scopus 로고    scopus 로고
    • Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy
    • American Society of Clinical Oncology European Society of Medical Oncology 21273511 10.1634/theoncologist.2010-0298 Epub 2011 Jan 27
    • Pinto C, Barone CA, Girolomoni G, Russi EG, Merlano MC, Ferrari D, Maiello E, American Society of Clinical Oncology, European Society of Medical Oncology (2011) Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist 16(2):228-238, Epub 2011 Jan 27
    • (2011) Oncologist , vol.16 , Issue.2 , pp. 228-238
    • Pinto, C.1    Barone, C.A.2    Girolomoni, G.3    Russi, E.G.4    Merlano, M.C.5    Ferrari, D.6    Maiello, E.7
  • 8
    • 4344646459 scopus 로고    scopus 로고
    • Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer
    • 15310767 10.1200/JCO.2004.11.057 1:CAS:528:DC%2BD2cXpsVGrsLg%3D
    • Perez-Soler R, Chachoua A, Hammond LA et al (2004) Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22:3238-3247
    • (2004) J Clin Oncol , vol.22 , pp. 3238-3247
    • Perez-Soler, R.1    Chachoua, A.2    Hammond, L.A.3
  • 9
    • 84884284716 scopus 로고    scopus 로고
    • Cetuximab dose-escalation study in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic and efficacy data of a randomized study Abstract 237
    • Van Cutsem E, Humblet Y, Gelderblom H et al Cetuximab dose-escalation study in patients with metastatic colorectal cancer (mCRC) with no or slight skin reactions on cetuximab standard dose treatment (EVEREST): Pharmacokinetic and efficacy data of a randomized study. 2007 ASCO Gastrointestinal Cancers Symposium. Abstract 237
    • 2007 ASCO Gastrointestinal Cancers Symposium
    • Van Cutsem, E.1    Humblet, Y.2    Gelderblom, H.3
  • 11
    • 0022992740 scopus 로고
    • Meta-analysis in clinical trials
    • 3802833 10.1016/0197-2456(86)90046-2 1:STN:280:DyaL2s7gsVamtA%3D%3D
    • DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188
    • (1986) Control Clin Trials , vol.7 , pp. 177-188
    • Dersimonian, R.1    Laird, N.2
  • 12
    • 49149097899 scopus 로고    scopus 로고
    • A phase II study of cetuximab/irinotecan in patients with heavily pretreated metastatic colorectal cancer: Predictive value of early specific toxicities
    • 18650196 10.3816/CCC.2008.n.035 1:CAS:528:DC%2BD1cXpvFKjtrc%3D
    • Gamucci T, Nelli F, Cianci G, Grassi G, Moscetti L, Sperduti I, Zeuli M, Cortesi E, D'Auria G, Pollera CF (2008) A phase II study of cetuximab/irinotecan in patients with heavily pretreated metastatic colorectal cancer: predictive value of early specific toxicities. Clin Colorectal Cancer 7(4):273-279
    • (2008) Clin Colorectal Cancer , vol.7 , Issue.4 , pp. 273-279
    • Gamucci, T.1    Nelli, F.2    Cianci, G.3    Grassi, G.4    Moscetti, L.5    Sperduti, I.6    Zeuli, M.7    Cortesi, E.8    D'Auria, G.9    Pollera, C.F.10
  • 15
    • 79953782046 scopus 로고    scopus 로고
    • Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): Safety, efficacy and improved secondary surgical resectability
    • 20401611 10.1007/s00280-010-1327-8
    • Lévi F, Karaboué A, Gorden L, Innominato PF, Saffroy R, Giacchetti S, Hauteville D, Guettier C, Adam R, Bouchahda M (2011) Cetuximab and circadian chronomodulated chemotherapy as salvage treatment for metastatic colorectal cancer (mCRC): safety, efficacy and improved secondary surgical resectability. Cancer Chemother Pharmacol 67(2):339-348
    • (2011) Cancer Chemother Pharmacol , vol.67 , Issue.2 , pp. 339-348
    • Lévi, F.1    Karaboué, A.2    Gorden, L.3    Innominato, P.F.4    Saffroy, R.5    Giacchetti, S.6    Hauteville, D.7    Guettier, C.8    Adam, R.9    Bouchahda, M.10
  • 16
    • 77955950937 scopus 로고    scopus 로고
    • Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: Are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy?
    • 20550522 10.1111/j.1349-7006.2010.01621.x 1:CAS:528:DC%2BC3cXhtFylu7bO
    • Paez D, Paré L, Espinosa I, Salazar J, del Rio E, Barnadas A, Marcuello E, Baiget M (2010) Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-EGFR-based therapy? Cancer Sci 101(9):2048-2053
    • (2010) Cancer Sci , vol.101 , Issue.9 , pp. 2048-2053
    • Paez, D.1    Paré, L.2    Espinosa, I.3    Salazar, J.4    Del Rio, E.5    Barnadas, A.6    Marcuello, E.7    Baiget, M.8
  • 17
    • 80054760645 scopus 로고    scopus 로고
    • Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer
    • 21340604 10.1007/s00280-011-1586-z 1:CAS:528:DC%2BC3MXht1eiu7zK
    • Park JH, Han SW, Oh DY, Im SA, Jeong SY, Park KJ, Kim TY, Bang YJ, Park JG (2011) Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer. Cancer Chemother Pharmacol 68(4):1045-1055
    • (2011) Cancer Chemother Pharmacol , vol.68 , Issue.4 , pp. 1045-1055
    • Park, J.H.1    Han, S.W.2    Oh, D.Y.3    Im, S.A.4    Jeong, S.Y.5    Park, K.J.6    Kim, T.Y.7    Bang, Y.J.8    Park, J.G.9
  • 19
    • 84856434000 scopus 로고    scopus 로고
    • Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer
    • 22215062 10.1038/bjc.2011.554 1:CAS:528:DC%2BC38XhtVGhurc%3D
    • Jehn CF, Böning L, Kröning H, Possinger K, Lüftner D (2012) Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer. Br J Cancer 106(2):274-278
    • (2012) Br J Cancer , vol.106 , Issue.2 , pp. 274-278
    • Jehn, C.F.1    Böning, L.2    Kröning, H.3    Possinger, K.4    Lüftner, D.5
  • 20
    • 72449200753 scopus 로고    scopus 로고
    • Correlation of KRAS status with clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated first-line with FOLFOX6 + cetuximab (FX + C) or FOLFIRI + cetuximab (FF + C): The CECOG/CORE1.2.001 trial
    • 10.1200/JCO.2008.21.7695 suppl; abstr 4055
    • Koza I Sr, Wrba F, Vrbanec D et al (2009) Correlation of KRAS status with clinical outcome in patients (pts) with metastatic colorectal cancer (mCRC) treated first-line with FOLFOX6 + cetuximab (FX + C) or FOLFIRI + cetuximab (FF + C): The CECOG/CORE1.2.001 trial. J Clin Oncol 27:15s, suppl; abstr 4055
    • (2009) J Clin Oncol , vol.27
    • Koza, Sr.I.1    Wrba, F.2    Vrbanec, D.3
  • 21
    • 36949039745 scopus 로고    scopus 로고
    • Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): A pooled analysis of five clinical trials
    • June 20 Supplement
    • Berlin J, Van Cutsem E, Peeters M et al (2007) Predictive value of skin toxicity severity for response to panitumumab in patients with metastatic colorectal cancer (mCRC): A pooled analysis of five clinical trials. J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement): 4134
    • (2007) J Clin Oncol 2007 ASCO Annual Meeting Proceedings Part I. , vol.25 , Issue.18 , pp. 4134
    • Berlin, J.1    Van Cutsem, E.2    Peeters, M.3
  • 22
    • 84928732974 scopus 로고    scopus 로고
    • Final results from study 181: Randomized phase III study of FOLFIRI with or without panitumumab (pmab) for the treatment of second-line metastatic colorectal cancer (mCRC)
    • abstr 387
    • Sobrero AF, Peeters M, Price TJ et al (2012) Final results from study 181: Randomized phase III study of FOLFIRI with or without panitumumab (pmab) for the treatment of second-line metastatic colorectal cancer (mCRC). J Clin Oncol 30 (suppl 4; abstr 387)
    • (2012) J Clin Oncol , vol.30 , Issue.SUPPL 4
    • Sobrero, A.F.1    Peeters, M.2    Price, T.J.3
  • 23
    • 84884288182 scopus 로고    scopus 로고
    • Final skin toxicity (ST) and patient-reported outcomes (PRO) results from PRIME: A randomized phase III study of panitumumab (pmab) plus FOLFOX4 (CT) for first-line metastatic colorectal cancer (mCRC)
    • abstr 531
    • Douillard YJ, Siena S, Tabernero J et al (2012) Final skin toxicity (ST) and patient-reported outcomes (PRO) results from PRIME: A randomized phase III study of panitumumab (pmab) plus FOLFOX4 (CT) for first-line metastatic colorectal cancer (mCRC). J Clin Oncol 30 (suppl 4; abstr 531)
    • (2012) J Clin Oncol , vol.30 , Issue.SUPPL. 4
    • Douillard, Y.J.1    Siena, S.2    Tabernero, J.3
  • 24
    • 79251650001 scopus 로고    scopus 로고
    • Randomized, open-label, phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST)
    • suppl; abstr 3529
    • Price TJ, Sobrero AF, Wilson G et al (2010) Randomized, open-label, phase III study of panitumumab (pmab) with FOLFIRI versus FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC): Efficacy by skin toxicity (ST). J Clin Oncol 28:15s, suppl; abstr 3529
    • (2010) J Clin Oncol , vol.28
    • Price, T.J.1    Sobrero, A.F.2    Wilson, G.3
  • 25
    • 84873701597 scopus 로고    scopus 로고
    • Cetuximab-related skin toxicity in metastatic colorectal cancer (mCRC) patients and its correlation with molecular markers: Results from the German AIO CRC 0104 trial
    • abstr 491
    • Stintzing S, Kapaun C, Laubender RP et al (2012) Cetuximab-related skin toxicity in metastatic colorectal cancer (mCRC) patients and its correlation with molecular markers: Results from the German AIO CRC 0104 trial. J Clin Oncol 30 (suppl 4; abstr 491)
    • (2012) J Clin Oncol , vol.30 , Issue.SUPPL. 4
    • Stintzing, S.1    Kapaun, C.2    Laubender, R.P.3
  • 26
    • 84868204016 scopus 로고    scopus 로고
    • Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: Results from a randomized trial of the GERMAN AIO CRC Study Group
    • 22644776 10.1002/ijc.27654 1:CAS:528:DC%2BC38XptVyis7o%3D
    • Stintzing S, Kapaun C, Laubender RP et al (2013) Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group. Int J Cancer 132(1):236-245
    • (2013) Int J Cancer , vol.132 , Issue.1 , pp. 236-245
    • Stintzing, S.1    Kapaun, C.2    Laubender, R.P.3
  • 27
    • 84865092896 scopus 로고    scopus 로고
    • Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: The randomized EVEREST study
    • 22753904 10.1200/JCO.2011.40.9243
    • Van Cutsem E, Tejpar S, Vanbeckevoort D et al (2012) Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study. J Clin Oncol 30(23):2861-2868
    • (2012) J Clin Oncol , vol.30 , Issue.23 , pp. 2861-2868
    • Van Cutsem, E.1    Tejpar, S.2    Vanbeckevoort, D.3
  • 28
    • 33749018219 scopus 로고    scopus 로고
    • Mechanisms of cutaneous toxicities to EGFR inhibitors
    • 16990857 10.1038/nrc1970 1:CAS:528:DC%2BD28XpvVClsr4%3D
    • Lacouture ME (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6:803-812
    • (2006) Nat Rev Cancer , vol.6 , pp. 803-812
    • Lacouture, M.E.1
  • 29
    • 0035256698 scopus 로고    scopus 로고
    • Untangling the ErbB signalling network
    • 10.1038/35052073 1:CAS:528:DC%2BD3MXivVWnt7k%3D
    • Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Molec Cell Biol 2:127-137
    • (2001) Nat Rev Molec Cell Biol , vol.2 , pp. 127-137
    • Yarden, Y.1    Sliwkowski, M.X.2
  • 30
    • 84885484471 scopus 로고    scopus 로고
    • Randomized phase III trial of cetuximab plus irinotecan alone for metastatic colorectal cancer (mCRC) in 1298 patients who have failed prior oxaliplatin-based therapy: The EPIC trial
    • Sobrero A, Fehrenbacher L, Rivera F et al (2007) Randomized phase III trial of cetuximab plus irinotecan alone for metastatic colorectal cancer (mCRC) in 1298 patients who have failed prior oxaliplatin-based therapy: the EPIC trial. In AACR Meeting Abstracts, p 3536-a
    • (2007) AACR Meeting Abstracts
    • Sobrero, A.1    Fehrenbacher, L.2    Rivera, F.3
  • 31
    • 34447264101 scopus 로고    scopus 로고
    • Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial
    • June 20 Supplement
    • Van Cutsem E, Nowacki M, Lang I et al (2007) Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 4000
    • (2007) J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I. , vol.25 , Issue.18 , pp. 4000
    • Van Cutsem, E.1    Nowacki, M.2    Lang, I.3
  • 32
    • 80051578949 scopus 로고    scopus 로고
    • Cetuximab and panitumumab in KRAS wild-type colorectal cancer: A meta-analysis
    • 10.1007/s00384-011-1149-0
    • Petrelli F, Borgonovo K, Cabiddu M et al (2011) Cetuximab and panitumumab in KRAS wild-type colorectal cancer: a meta-analysis. Int J Color Dis 26(7):823-833
    • (2011) Int J Color Dis , vol.26 , Issue.7 , pp. 823-833
    • Petrelli, F.1    Borgonovo, K.2    Cabiddu, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.